Prognostic Assessment and Adjuvant Treatment Strategies Within Early-Stage, Sporadic Triple Negative Breast Cancer Patients
Robert Königsberg(Kaiser-Franz-Josef-Spital), Christian F. Singer(Comprehensive Cancer Center Vienna), Roland Kurzawa(Lauder Business School), Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy), Marcus Hudec(University of Vienna), Robert Zeillinger(Comprehensive Cancer Center Vienna), Georg Pfeiler(Medical University of Vienna)
Cited by 8
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403